3 Australian Founder Led Stocks With Revenue Growth Up To 37%

Higher interest rates are squeezing Australian households, with more people taking second jobs just to keep up with mortgages and rising bills. That kind of pressure can punish companies that depend on cheap money, yet it can highlight founders who stay personally invested and keep course corrections tight. This article looks at three founder-led Australian stocks from our screener that illustrate how a long-term vision and significant personal investment can matter when money is no longer easy.

The three founder-led stocks below are just a sample, and the full screen surfaced 83 more businesses with equally strong founder stories that are not covered here. To go straight to the full list and start analyzing which leaders you want to back for the long haul, head into the Founder-Led Companies screener.

Macquarie Technology Group (ASX:MAQ)

Macquarie Technology Group runs telecom, cloud computing, cyber security and data centre services for Australian corporate and government clients. Its founder-led team places clear emphasis on Cloud Services & Government, which produced about A$235 million of the A$390 million top line, alongside Telecom at roughly A$105 million and Data Centres at about A$87 million, with a market value near A$1.5 billion.

Macquarie Technology Group pairs founder control with a cloud and government unit that brought in around A$236 million of A$390 million revenue, all inside a business valued near A$1.5 billion. Investors who focus on founder-led stories may note the combination of a premium P/E and an expanding cloud focus, particularly in light of one less visible pressure on profitability that could become an important factor.

That hidden pressure is worth unpacking through the 1 key reward and 1 important major warning sign for a clearer read on where Macquarie Technology Group’s next gear could come from.

Mesoblast (ASX:MSB)

Mesoblast is a founder-led regenerative medicine business building therapies from its mesenchymal lineage cell platform, with all of its roughly US$120 million revenue tied to developing and commercializing this cell-based pipeline and a market value of about A$2.8b.

For the Founder-Led Companies theme, Mesoblast puts the emphasis squarely on a long-haul clinical vision, where management’s commitment to the cell-therapy platform is central and commercial traction is starting to reflect years of focused development work.

"The first and only FDA approved mesenchymal stromal cell product in the U.S., Ryoncil, together with over 1,100 patents and established commercial scale manufacturing, positions Mesoblast to benefit if cell therapies gain wider medical adoption."

What happens to Mesoblast’s earnings power hinges on how one future shift in real-world treatment behavior and payer appetite unfolds.

If that shift breaks Mesoblast’s way, read the full narrative for Mesoblast to see how the FDA decision, patents and payer behavior could quickly change expectations.

Harvey Norman Holdings (ASX:HVN)

Harvey Norman Holdings is a founder-influenced retailer built around big-ticket furniture, bedding and electronics, with franchise and property operations reflecting that legacy mindset. The group generated around A$952 million in New Zealand, A$777 million in Ireland and A$787 million in Singapore and Malaysia, with smaller contributions from other regions, and carries a market value near A$5.2 billion.

Harvey Norman fits the founder-led screen through Gerry Harvey’s large stake and decades-long imprint on franchising and property decisions, which keeps the focus on building a durable business rather than chasing quick sales spikes.

"It is worth noting, however, that just over 20% of 2025 profit can be attributed to property revaluations. These are non-cash gains that can be volatile and are not recurring operational earnings."

What happens when one quiet shift in how those legacy assets earn their keep filters through to everyday margins will matter a lot.

As that shift plays through Harvey Norman’s income statement, the full narrative for Harvey Norman Holdings maps how property revaluations, cash earnings and founder influence could be quietly decoupling before the market fully catches on.

Seeking Alternatives Before Everyone Else

Fresh ideas move first, not last. Markets shift, stories gain momentum and the easy entry points get caught quickly. Scan under-the-radar opportunities before the crowd and get in early.

• Target reliable income streams while others chase headlines by scanning a curated batch of income plays through the 3 dividend fortresses.
• Catch early movers in critical infrastructure trends by filtering potential growth stories using the 39 power grid technology and infrastructure stocks.
• Track early-stage momentum in future-facing materials by zeroing in on curated producers through the 17 top copper producer stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com